"This $153,000 rattlesnake bite is everything wrong with American health care"
Earlier this month a guy named Todd Fassler was bitten by a rattlesnake in San Diego,
KGTV San Diego reports. In itself this isn't terribly unusual—the CDC
estimates that roughly 7,000 to 8,000 people a year get bit by a venomous snake in the U.S. And somewhere between five and six people
die from these bites each year.
What raised eyebrows, though, was Fassler's hospital bill—all $153,000 of it.
The bulk of his hospital bill—$83,000 of it— is due to pharmacy charges. Specifically, charges for the antivenin used to treat the bite. KGTV
reports that Fassler depleted the antivenin supplies at two local hospitals during his five-day visit. Nobody expects antivenin to be cheap. But $83,000?
There's currently only one commercially-available antivenin for treating venomous snakebites in the U.S. --
CroFab, manufactured by U.K.-based
BTG plc. And with a stable market of 7,000 to 8,000 snakebite victims per year and no competitors, business is pretty good. BTG's
latest annual report shows CroFab sales topped out at close to $63 million British pounds, or $98 million dollars last fiscal year.
BTG has
fought aggressively to keep competitors off the market. A competing product, Anavip, just
received FDA approval this year and likely won't be on the market until late 2018. This lack of competition is one reason why snakebite treatments rack up such huge hospital bills -- $
55,000. $
89,000. $
143,000. In May of this year, a snakebit Missouri man died after refusing to seek medical care, saying
he couldn't afford the bill.
http://www.washingtonpost.com/blogs...s-everything-wrong-with-american-health-care/